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Proteins belonging to the TIS11/TTP/
ZFP gene family were originally described 
as important negative regulators of the 
inflammatory response,1 owing to their 
ability to bind specific AU-rich elements 
located in the 3'-UTR region of mRNAs 
encoding a variety of pro-inflammatory 
proteins, thereby triggering their de-
adenylation and subsequent degradation. 
Over the years, the number of their puta-
tive and validated targets, among which 
there are several oncogenes,2,3 grew sig-
nificantly and they became more and 
more involved in the control of a growing 
number of cellular processes encompass-
ing differentiation,4 apoptosis5 and even 
angiogenesis.6 In addition, many evi-
dences were published suggesting that the 
expression of TIS11/TTP genes is often 
decreased in many cancers compared to 
normal tissues.7 Altogether, these data are 
pushing several researchers, the present 
writer included, to suggest with reason-
able confidence that these proteins might 
represent a novel group of tumor suppres-
sor genes. And indeed this hypothesis 
seems to be correct, since family members 
ZFP36 and ZFP36L1 are really capable 
of binding and triggering degradation of 
different mRNAs encoding a number of 
oncogenes or genes involved in prolifera-
tion and apoptosis pathways. Nevertheless, 
before accepting this idea, there is at least 
one question that requires an answer. In 
fact, the scientific community is used to 
call “oncogenes” those mutated or overex-
pressed genes whose deregulated activity 
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is sufficient to determine a change in cell 
physiology that can ultimately lead to 
tumor transformation. So, if ZFP36 and 
ZFP36L1 are capable of downregulat-
ing the expression of several among these 
genes at once, they should, when overex-
pressed, determine a dramatic influence 
on the behavior of cells. In other words, 
how come we didn’t focus our attention 
on these tumor suppressors before? The 
answer to this question probably resides in 
at least two issues that still require to be 
fully understood, that could explain why 
experiments aimed to restore the expres-
sion of ZFPs in cancer cells do determine 
a regression of the tumor phenotype, but 
not always as severe as one could expect 
considering the broad range of target 
genes mRNAs that could be degraded. 
The first issue involves a possible inter-
play occurring between ZFPs and mRNA 
binding proteins belonging to other fami-
lies, such as HuR, that act by stabilizing 
their mRNA targets and that are known 
to play a positive role in the genesis of can-
cer.8 This idea allows to hypothesize the 
existence of a network of mRNA binding 
proteins whose final balance, similarly to 
what happens in the control of apoptosis 
mediated by bcl family genes, determines 
the fate of the host cell. The second issue 
involves the control of TIS11/TTP genes 
expression. Genes belonging to this family 
are transiently expressed in physiological 
conditions to cease the cellular response to 
growth factors9 or to control the inflamma-
tory response.1 Such observations suggest 
a tight regulation at the promoter level, 
where in both ZFP36 and ZFP36L1 genes 
wide CpG islands are also present, and an 
equally tight regulation at the post tran-
scriptional and possibly post-translational 
levels. In particular, ZFPs carry AU-rich 
elements in their own 3'-UTR mRNAs, 
therefore they are capable of auto- 
limiting their own expression. This is often 
observed in overexpression assays where 
the increase of ectopic ZFP36 expression 
is coupled to a decrease of the endogenous 
protein and mRNA. The nature of TIS11/
TTP genes, the complexity of their regula-
tion and the volatility of their endogenous 
expression eventually explain why these 
genes were not recognized as tumor sup-
pressors before. Therefore, although stud-
ies aimed to find, validate and describe 
new targets of TIS11/TTP proteins will 
remain important, the real challenge 
now is to understand how these genes are 
regulated in order to fully exploit their 
anti-oncogenic potential. In general, the 
study of the TIS11/TTP family confirms 
that mRNA stability is a field of growing 
importance to develop novel therapeutic 
approaches to understand and treat cancer.
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